AirSculpt Technologies, Inc. provides premium body contouring procedures through AirSculpt offices. Its AirSculpt method is a minimally invasive treatment for fat removal, skin tightening, targeted body sculpting, and fat transfer procedures that use a patient’s own fat cells.
Company news centers on operating results, same-center and same-store sales trends, case volume, revenue, adjusted EBITDA, guidance, marketing initiatives, new procedure categories, balance sheet activity, and governance changes. Updates also address the company’s positioning within aesthetics demand tied to GLP-1 use and its direct medical procedure services model.
AirSculpt Technologies (NASDAQ: AIRS) announced its first nationwide Open House, “The Gift of Body Confidence,” for November 12, 2026. The event will take place across 31 centers and virtually, offering prospective and existing patients personalized consultations, educational discussions and question-and-answer sessions with surgeons. Seasonal packages and promotions will also be available.
AirSculpt Technologies (AIRS) will participate in the A.G.P. Virtual Consumer Showcase, with a management fireside chat on November 11, 2026.
The presentation is scheduled for 10:30 a.m. Eastern Time and will be webcast live with a replay available. The webcast link will appear in the Events & Presentations section of the company’s investor relations website.
AirSculpt Technologies (AIRS) reported third-quarter revenue of $31.9 million and lowered its full-year outlook as procedure volumes declined. Revenue fell 8.7% year over year, while same-center cases decreased 9.6%. Net loss narrowed to $7.173 million from $9.512 million, but adjusted EBITDA, a non-GAAP earnings measure, fell to $393,000 from $3.039 million.
For the first nine months, revenue declined 3.5% to $114.2 million. AirSculpt now expects approximately $144 million–$146 million in 2026 revenue and approximately $9 million–$10 million in adjusted EBITDA, below its previous ranges. On November 5, it completed refinancing with a $39.0 million funded senior secured term loan and an undrawn revolving facility of up to $5.0 million, maturing November 5, 2031. September 30 cash was $15.182 million; third-quarter operating cash outflow was $3.475 million.
AirSculpt Technologies (NASDAQ: AIRS) will report third-quarter 2026 financial results before market open on November 6, 2026. A conference call will follow that day at 8:30 a.m. Eastern Time, with a live webcast available through the company’s investor relations website. A webcast replay will remain available for approximately 90 days.
AirSculpt Technologies (NASDAQ:AIRS) reported fiscal Q2 2026 revenue of $42.9 million, down 3% year over year, on case volume of 3,376, down 0.5%. Net loss widened to $1.1 million from $0.6 million, while Adjusted EBITDA declined to $4.9 million from $5.8 million, with an 11.5% margin.
Same-center cases grew 1.0% in Q2 and 1.1% year-to-date, with essentially flat same-center sales. Year-to-date revenue fell 1.3% to $82.3 million and net loss was $3.5 million. According to the company, an exclusive partnership with AlloClae is expected to broaden its injectable adipose matrix offering.
Since early 2025, gross debt fell by about $30 million to $44.2 million and cash increased by roughly $10 million to $18.8 million. AirSculpt reaffirmed full-year 2026 revenue at the lower end of its $151–$157 million range and reduced Adjusted EBITDA guidance to $12–$14 million. A term loan amendment extends maturity to November 2027 and adds prepayment requirements tied to future equity issuance.
AirSculpt Technologies (NASDAQ: AIRS) will release its second quarter fiscal 2026 financial results before the market opens on Monday, August 10, 2026, followed by a conference call at 8:30 a.m. Eastern Time, accessible via telephone and live webcast on its investor relations website.
The company will also participate in Canaccord Genuity's 46th Annual Growth Conference at the InterContinental Boston Hotel on August 11, 2026, with a management presentation at 4:30 p.m. Eastern Time, which will be webcast live for investors.
AirSculpt Technologies (NASDAQ:AIRS) will participate in two June 2026 investor conferences. Management will present and hold investor meetings at both events, with fireside chats webcast live and available for replay on the company’s investor relations website.
The conferences are hosted by TD Cowen and Oppenheimer.
AirSculpt Technologies (NASDAQ:AIRS) reported first quarter fiscal 2026 results for the period ended March 31, 2026. Key metrics: revenue $39.4M (flat), case volume 3,082 (+0.2% vs FY25 Q1), same center sales +1%, net loss $2.4M, and adjusted EBITDA $3.3M. The company reaffirmed full‑year 2026 guidance of $151–$157M revenue and $15–$17M adjusted EBITDA. Liquidity included $16.7M cash, ~$45.6M gross debt, $5.0M revolver capacity, and $14.6M raised via ATM with $11.4M debt paydown in Q1.
AirSculpt Technologies (NASDAQ: AIRS) will report Q1 2026 results before market open on May 8, 2026, followed by a conference call at 8:30 a.m. ET. The call includes domestic and international dial-in numbers and a live webcast via the company investor relations site.
The webcast replay will be available for about 90 days. Management will present at the Wolfe Research Global Consumer Growth Conference (virtual) on May 18, 2026 and at the LD Micro Invitational (Los Angeles) on May 19, 2026; both presentations will be viewable on the investor relations page.
AirSculpt Technologies (NASDAQ:AIRS) reported corrected fourth-quarter and full-year 2025 results, updating Adjusted EBITDA and related metrics due to a one-time non-cash London facility adjustment. FY2025 revenue fell to $151.8M, Adjusted EBITDA was $12.5M, and net loss was $11.7M. The company provided 2026 guidance and noted improved same-store sales in early 2026.
Liquidity included $8.4M cash at Dec 31, 2025, $5.0M revolver capacity, and gross debt reduced to ~$45.0M after an ATM raise and debt paydown in Q1 2026.